4.01
-0.04(-0.99%)
Currency In USD
| Previous Close | 4.05 |
| Open | 4.04 |
| Day High | 4.1 |
| Day Low | 3.96 |
| 52-Week High | 7.73 |
| 52-Week Low | 2.9 |
| Volume | 2.54M |
| Average Volume | 4.13M |
| Market Cap | 353.91M |
| PE | -3.75 |
| EPS | -1.07 |
| Moving Average 50 Days | 4.47 |
| Moving Average 200 Days | 4.53 |
| Change | -0.04 |
If you invested $1000 in Altimmune, Inc. (ALT) since IPO date, it would be worth $30.11 as of January 14, 2026 at a share price of $4.01. Whereas If you bought $1000 worth of Altimmune, Inc. (ALT) shares 5 years ago, it would be worth $295.5 as of January 14, 2026 at a share price of $4.01.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
GlobeNewswire Inc.
Jan 05, 2026 12:30 PM GMT
Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDAGAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharma
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
GlobeNewswire Inc.
Dec 19, 2025 11:30 AM GMT
Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing Favorable tolerabilit
Altimmune Announces CEO Transition and Succession Plan
GlobeNewswire Inc.
Dec 01, 2025 12:30 PM GMT
Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a